as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹4,611.0
Change
+0.3 (0.01%)
Open
₹4,604.0
Prev. Close
₹4,610.7
Day High
₹4,670.3
Day Low
₹4,592.6
Volume Analysis
Traded
238,630
Delivered
150,045
Delivery %
62.88%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (27.4%)
- •Strong operating margin (33.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year EPS growth (20.2%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹4,734.36 | ₹4,702.33 | ₹4,656.66 | ₹4,624.63 | ₹4,578.96 | ₹4,546.93 | ₹4,501.26 |
| Fibonacci | ₹4,702.33 | ₹4,672.65 | ₹4,654.31 | ₹4,624.63 | ₹4,594.95 | ₹4,576.61 | ₹4,546.93 |
| Camarilla | ₹4,632.37 | ₹4,625.25 | ₹4,618.12 | ₹4,624.63 | ₹4,603.88 | ₹4,596.76 | ₹4,589.63 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+19.82%
1 Week
-2.46%
1 Month
+1.26%
3 Months
-5.83%
6 Months
+2.78%
1 Year
+23.9%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹833.46
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
9.08%
Net margin 12.06% × asset turnover 0.31x × equity multiplier 2.43x
Company Overview
Sector
Healthcare
Market Cap
₹177,632 Cr
P/E (TTM)
81.8
ROE
27.4%
Book Value
₹483.0
Face Value
₹5.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Torrent Pharmaceuticals L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 67/100. The strongest factor is Liquidity (93/100), while Valuation (3/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (27.4%); strong operating margin (33.0%); promoter holding is falling. Strong 3-year EPS growth (20.2%).
TopFund Score — Fundamentals Quality
67/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- +Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
- +Company has been maintaining a healthy dividend payout of 57.8%
- −Stock is trading at 9.67 times its book value
- −Promoter holding has decreased over last quarter: -7.53%
- −The company has delivered a poor sales growth of 11.8% over past five years.
- −Company might be capitalizing the interest cost
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Torrent Pharma redeemed and repaid ₹100 crore unlisted secured NCDs on 09-Nov-26.
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (LODR) Regulations, 2015
Commercial Tax Officer imposed ₹3.12 crore GST penalty on JB Chemicals for FY2020-21 to FY2023-24.
KFin Technologies’ corporate office shifts to Hyderabad from 1 December 2026; registered office unchanged.
Newspaper advertisement in respect of special window for transfer and dematerialisation requests of physical shares
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,660 | 2,732 | 2,745 | 2,859 | 2,889 | 2,809 | 2,959 | 3,178 | 3,302 | 3,303 | 4,197 | 4,921 | 4,979 |
| Expenses + | 1,835 | 1,863 | 1,862 | 1,955 | 1,950 | 1,895 | 1,995 | 2,146 | 2,219 | 2,215 | 2,841 | 3,257 | 3,313 |
| Operating Profit | 825 | 869 | 883 | 904 | 939 | 914 | 964 | 1,032 | 1,083 | 1,088 | 1,356 | 1,664 | 1,666 |
| OPM % | 31.0% | 32.0% | 32.0% | 32.0% | 32.0% | 33.0% | 33.0% | 32.0% | 33.0% | 33.0% | 32.0% | 34.0% | 33.0% |
| Other Income + | 26 | 55 | 31 | 24 | -16 | 33 | -42 | -37 | -40 | -23 | -83 | -33 | -20 |
| Interest | 91 | 80 | 80 | 75 | 64 | 57 | 56 | 56 | 48 | 45 | 236 | 305 | 300 |
| Depreciation | 201 | 213 | 203 | 197 | 198 | 199 | 201 | 201 | 204 | 206 | 508 | 593 | 609 |
| Profit before tax | 559 | 631 | 631 | 656 | 661 | 691 | 665 | 738 | 791 | 814 | 529 | 733 | 737 |
| Tax % | 31.0% | 30.0% | 29.0% | 30.0% | 31.0% | 27.0% | 25.0% | 26.0% | 25.0% | 22.0% | 31.0% | 23.0% | 28.0% |
| Net Profit + | 386 | 443 | 449 | 457 | 453 | 503 | 498 | 548 | 591 | 635 | 364 | 566 | 534 |
| EPS in Rs | 11 | 13 | 13 | 14 | 13 | 15 | 15 | 16 | 17 | 19 | 11 | 17 | 14 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 16 | 10 | 10 | 10 | 9 | 3 | 8 | 11 | 14 | 18 | 42 | 55 | 51 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 4,636 | 6,687 | 5,816 | 5,950 | 7,673 | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 11,516 | 13,980 | 17,400 |
| Expenses + | 3,616 | 3,954 | 4,438 | 4,601 | 5,690 | 5,769 | 5,524 | 6,077 | 6,778 | 7,360 | 7,795 | 9,421 | 11,626 |
| Operating Profit | 1,020 | 2,733 | 1,377 | 1,349 | 1,983 | 2,170 | 2,480 | 2,431 | 2,842 | 3,368 | 3,721 | 4,558 | 5,774 |
| OPM % | 22.0% | 41.0% | 24.0% | 23.0% | 26.0% | 27.0% | 31.0% | 29.0% | 30.0% | 31.0% | 32.0% | 33.0% | 33.0% |
| Other Income + | 286 | 32 | 223 | 299 | -300 | 121 | 57 | -288 | 45 | 146 | -1 | -182 | -159 |
| Interest | 175 | 184 | 206 | 308 | 504 | 451 | 353 | 255 | 333 | 354 | 252 | 385 | 886 |
| Depreciation | 191 | 238 | 307 | 409 | 618 | 654 | 658 | 662 | 707 | 808 | 795 | 1,119 | 1,916 |
| Profit before tax | 940 | 2,343 | 1,088 | 931 | 562 | 1,187 | 1,526 | 1,226 | 1,847 | 2,352 | 2,673 | 2,872 | 2,813 |
| Tax % | 20.0% | 26.0% | 14.0% | 27.0% | 22.0% | 14.0% | 18.0% | 37.0% | 33.0% | 30.0% | 28.0% | 26.0% | — |
| Net Profit + | 751 | 1,733 | 934 | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,911 | 2,138 | 2,099 |
| EPS in Rs | 22 | 51 | 28 | 20 | 13 | 30 | 37 | 23 | 37 | 49 | 56 | 64 | 60 |
| Dividend Payout % | 25.0% | 34.0% | 25.0% | 35.0% | 66.0% | 53.0% | 47.0% | 105.0% | 60.0% | 57.0% | 57.0% | 59.0% | — |
| Sales growth | 11 | 44 | -13 | 2 | 29 | 3 | 1 | 6 | 13 | 12 | 7 | 21 | 42 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 2,406 | 3,409 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 | 7,421 | 8,219 | 18,183 |
| Borrowings + | 2,740 | 2,352 | 2,510 | 6,462 | 6,038 | 5,784 | 4,874 | 4,070 | 5,369 | 4,022 | 3,202 | 15,026 | 14,107 |
| Other Liabilities + | 2,589 | 3,040 | 2,740 | 3,159 | 3,351 | 3,402 | 3,363 | 2,884 | 3,043 | 3,627 | 3,603 | 20,200 | 12,135 |
| Total Liabilities | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 | 43,614 | 44,615 |
| Fixed Assets + | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,121 | 8,138 | 7,947 | 33,191 | 32,621 |
| CWIP | 678 | 1,042 | 519 | 647 | 617 | 712 | 889 | 630 | 765 | 361 | 478 | 641 | 404 |
| Investments | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 | 156 | 948 | 2,160 |
| Other Assets + | 4,011 | 4,206 | 4,589 | 5,249 | 5,395 | 5,763 | 5,940 | 5,628 | 5,524 | 5,834 | 5,815 | 8,833 | 9,430 |
| Total Assets | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 | 43,614 | 44,615 |
| Equity Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 190 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 810 | 2,742 | 1,009 | 894 | 1,798 | 1,393 | 2,005 | 1,803 | 2,368 | 3,266 | 2,585 | 3,023 |
| Cash from Investing Activity + | -2,113 | -869 | -798 | -4,677 | -246 | 229 | -444 | -196 | -2,335 | -160 | -549 | -12,630 |
| Cash from Financing Activity + | 1,212 | -1,435 | -193 | 3,417 | -1,314 | -1,549 | -1,651 | -1,781 | 77 | -2,780 | -2,298 | 10,151 |
| Net Cash Flow | -90 | 437 | 18 | -366 | 238 | 73 | -89 | -174 | 110 | 327 | -262 | 544 |
| Free Cash Flow | 574 | 2,150 | 523 | 105 | 1,138 | 990 | 1,671 | 1,607 | 1,953 | 2,967 | 1,991 | 2,386 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 85 | 121 | 101 | 87 | 105 | 77 | 88 | 91 | 97 | 112 | 86 | 84 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 7.46% | 7.34% | 7.25% | 7.21% | 7.17% | 7.02% | 6.93% | 6.47% | 6.41% | 6.55% | 6.42% | 8.54% |
| Promoters | 71.25% | 71.25% | 71.25% | 71.25% | 68.31% | 68.31% | 68.31% | 68.31% | 68.31% | 68.31% | 68.31% | 60.78% |
| Government | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.0% | 0.1% | 0.09% |
| FII | 14.08% | 14.14% | 14.22% | 14.46% | 16.17% | 16.31% | 16.09% | 15.92% | 16.13% | 16.18% | 15.44% | 17.22% |
| DII | 7.11% | 7.15% | 7.17% | 6.98% | 8.25% | 8.25% | 8.54% | 9.17% | 9.05% | 8.96% | 9.73% | 13.37% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Torrent Pharmaceuticals L (this stock) | 177,632 | 81.8 | 9.67 | 27.4% |
| Apollo Hospitals Enter. L | 125,893 | 55.6 | 11.86 | 21.5% |
| Laurus Labs Limited | 125,380 | 93.6 | 20.73 | 18.3% |
| Zydus Lifesciences Ltd | 118,693 | 26.2 | 4.27 | 21.2% |
| Dr. Reddy S Laboratories | 115,092 | 41.1 | 2.96 | 11.2% |
| Cipla Ltd | 112,563 | 36.2 | 3.18 | 11.6% |
| Mankind Pharma Limited | 108,424 | 46.5 | 6.16 | 13.1% |
Which Mutual Funds Hold Torrent Pharmaceuticals L?
Frequently Asked Questions about Torrent Pharmaceuticals L
Torrent Pharmaceuticals L (TORNTPHARM) closed at ₹4,611.0 on NSE on 19 November 2026, up 0.3 (0.01%) from the previous close.
Torrent Pharmaceuticals L trades on the NSE (National Stock Exchange of India) under the symbol TORNTPHARM.
Torrent Pharmaceuticals L has a trailing twelve-month P/E (price-to-earnings) ratio of 81.8.
Torrent Pharmaceuticals L has a dividend yield of 0.81%.
Torrent Pharmaceuticals L's 52-week high is ₹5,250.0 and its 52-week low is ₹3,672.0.
Torrent Pharmaceuticals L has a market capitalisation of ₹177,632 crore.
Torrent Pharmaceuticals L has a TopFund Quality Score of 67/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Torrent Pharmaceuticals L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.